In-Cell ELISA Protocol: Cell-Based Protein Quantification and Normalisation

In-Cell ELISA is a plate-based immunocytochemistry method for measuring protein abundance or post-translational modification directly in fixed cultured cells. It is also described as cell-based ELISA, cytoblot, or, in fluorescence-based formats, an In-Cell Western assay. The method combines the throughput of a microplate assay with antibody-based detection of cellular targets.

Because cells remain attached to the plate, In-Cell ELISA avoids cell lysis, gel electrophoresis and membrane transfer. It is well suited to screening experiments, signalling studies, drug-response assays, phosphorylation analysis and relative protein-expression measurements across many conditions.

Important: unlike a conventional sandwich ELISA, In-Cell ELISA does not measure soluble analyte concentration. It measures antibody signal in fixed cells. Reliable interpretation therefore depends on consistent cell number, appropriate fixation/permeabilisation, validated antibodies and a robust normalisation strategy.

When to use In-Cell ELISA

• Screen protein-expression changes across many treatments or doses.
• Measure phosphorylation or another post-translational modification after stimulation.
• Compare signalling responses across time courses.
• Quantify relative target abundance in adherent cultured cells.
• Screen antibodies or compounds in a 96- or 384-well format.
• Measure a target while normalising to cell number or a second cellular marker.

In-Cell ELISA compared with western blotting

Equipment required

• Cell-culture-treated 96-well or 384-well microplate suitable for the chosen readout
• CO₂ incubator
• Calibrated single- and multichannel pipettes
• Plate washer or validated manual wash setup
• Microplate reader for colorimetric or fluorescent readout, or compatible near-infrared imager for In-Cell Western formats
• Plate shaker where appropriate

Reagents

• Adherent cultured cells
• Experimental treatment or stimulus
• PBS
• Fixative, commonly paraformaldehyde/formaldehyde
• Permeabilisation buffer for intracellular targets
• Blocking buffer
• Primary antibody validated for ICC/IF or cell-based detection
• Enzyme-conjugated primary antibody or species-specific enzyme-/fluorophore-conjugated secondary antibody
• Substrate appropriate to the detection enzyme if using colorimetric detection
• Cell-number or total-protein normalisation reagent

Experimental design

Plan plate layout before seeding. Include enough wells for biological conditions, technical replicates, antibody controls and normalisation. Edge wells can behave differently because of evaporation, so if the assay is sensitive to edge effects consider filling perimeter wells with sterile PBS or medium where appropriate and using internal wells for quantitative comparisons.

Cell-seeding optimisation

Cell number is a major source of variability. Signal should increase approximately proportionally with cell number over the working range. Before a large experiment, seed a dilution series of cells and identify a density that gives a reproducible signal without reaching confluence during the treatment period.

• Avoid overconfluent wells, which can alter signalling and antigen accessibility.
• Use the same passage range across comparative experiments.
• Mix cell suspensions frequently while plating to reduce well-to-well variation.
• Allow sufficient time for cells to attach before treatment.

Fixation and permeabilisation considerations

Published In-Cell Western methods commonly use aldehyde fixation followed by target-dependent permeabilisation and blocking. Cross-linking fixation preserves cellular architecture but can reduce accessibility of some epitopes, while alcohol fixation can improve access for selected targets at the expense of membrane and structural preservation. The fixation method should therefore be validated with a positive biological control and, where possible, an orthogonal assay.

Permeabilisation is necessary for intracellular targets but can be omitted for extracellular epitopes when the target is accessible without membrane disruption. Detergent concentration should be kept as mild as possible while still allowing antibody access.

In-Cell ELISA protocol

1. Seed cells. Plate adherent cells at a density that will remain within the validated working range throughout treatment. Allow cells to attach and recover.
2. Treat or stimulate. Apply drug, cytokine, ligand, inhibitor or other experimental condition. Include vehicle and untreated controls where relevant.
3. Remove medium carefully. Aspirate without disturbing the monolayer. Gently wash with PBS if required by the experimental design.
4. Fix the cells. A common starting condition is approximately 4% paraformaldehyde/formaldehyde for 10–20 minutes at room temperature. Published fixed-cell assays commonly use approximately 10–20 minutes of aldehyde fixation as a starting range. Optimise if the antibody or target requires a different fixation method.
5. Wash thoroughly. Remove residual fixative with repeated PBS washes.
6. Permeabilise if required. Add a validated permeabilisation buffer for intracellular targets. Triton X-100, saponin and related detergents are common choices. Omit or reduce this step for cell-surface targets.
7. Block. Incubate with blocking buffer to reduce non-specific antibody binding. A approximately 1–2 hours at room temperature is a reasonable starting point for many custom assays.
8. Wash. Remove unbound blocking reagent before antibody incubation.
9. Add primary antibody. Dilute the antibody in the recommended incubation buffer. Use a datasheet-specified ICC/IF or In-Cell ELISA dilution where available; otherwise perform a titration.
10. Incubate. Overnight incubation at 4°C is commonly used for primary antibodies in cell-based assays, although shorter room-temperature incubations can work for some antibodies.
11. Wash thoroughly. Repeated washing is essential to reduce background.
12. Add detection antibody. For indirect detection, add an enzyme- or fluorophore-conjugated species-specific secondary antibody at its validated concentration. If using a directly conjugated primary antibody, this step is not required.
13. Incubate and wash. A 1–2 hour room-temperature secondary incubation is common. Wash thoroughly after incubation.
14. Develop the signal. For HRP/TMB assays, add TMB and develop for a fixed time before adding stop solution. For fluorescence-based assays, read the appropriate excitation/emission channel.
15. Measure the normalisation signal. Quantify cell number, total protein or a stable reference marker in the same or parallel wells using a validated method.
16. Read the plate. Measure absorbance or fluorescence using consistent settings across all comparable wells.

Normalisation strategies

Normalisation is essential because raw antibody signal can change simply because one well contains more cells than another.

• Cell stain: a non-specific whole-cell or nuclear stain can provide a direct estimate of cell number.
• Total protein: a plate-compatible total-protein stain can normalise for biomass.
• Reference protein: a second antibody can measure a stable housekeeping or structural protein, but that target must be validated as unchanged by the treatment.

Published In-Cell Western studies commonly use a second target, DNA stain or whole-cell stain for normalisation. Whatever normalisation signal is chosen should be shown experimentally to remain proportional to cell number and stable across the treatment conditions being tested.

Controls

• No-primary control: detects non-specific secondary-antibody or detection-reagent signal.
• Positive biological control: cells known to express the target or respond to the chosen stimulus.
• Negative biological control: knockout, knockdown, unstimulated or target-negative cells where available.
• Isotype control: useful for selected assays but should not replace biological controls.
• Cell-number control: verifies that treatment did not simply reduce cell number or viability.
• Reference antibody: useful for multiplex or normalised readouts if validated as stable.

Phosphorylation assays

In-Cell ELISA is frequently used to quantify phosphoproteins after stimulation. Use phospho-specific antibodies validated for fixed-cell applications, include phosphatase inhibitors during any relevant handling prior to fixation, and pair the phospho readout with either total target protein or a robust cell-normalisation signal. A change in phospho-signal should not automatically be interpreted as a change in phosphorylation stoichiometry if total target abundance also changes.

Data analysis

1. Subtract appropriate background from raw target signal.
2. Normalise target signal to cell number, total protein or the validated reference target.
3. Express treatment effects relative to the appropriate control group.
4. Use biological replicates for inferential comparisons rather than treating technical replicate wells as independent experiments.

Recommendations and warnings

• Normalisation is not optional for quantitative comparisons. Treatment-induced cell loss can mimic reduced protein expression.
• Validate the antibody in fixed cells. WB performance alone does not prove the antibody will recognise its epitope after fixation.
• Keep the assay within a linear cell-density range. Overconfluent wells compress dynamic range and can alter signalling.
• For phosphoproteins, measure total target where possible. A fall in phospho-signal can reflect less total protein rather than reduced phosphorylation stoichiometry.
• Do not use a housekeeping target without validation. Drug treatment, stress or cell-cycle changes can alter common reference proteins.

Limitations

• No molecular-weight information is obtained, so non-specific antibody binding cannot be distinguished by band size as in western blotting.
• Cell loss during washing can bias results.
• Fixation and permeabilisation can alter epitope accessibility.
• Cell number and confluence strongly influence raw signal.
• Reference proteins can change with treatment and must be validated before use for normalisation.
• Very high target abundance can saturate colorimetric or fluorescent detection.

Troubleshooting

Warnings and common analytical traps

• Do not interpret raw signal without cell-number normalisation. Cytotoxic or anti-proliferative treatments can reduce target signal simply by reducing the number of cells in the well.
• Do not assume a housekeeping protein is stable. Validate the reference target under every treatment class used in the study.
• Do not compare saturated wells. Once the detector or substrate response plateaus, true biological differences are compressed.
• Do not infer antibody specificity from plate signal alone. Confirm specificity with a positive/negative biological control and, where possible, western blot or knockout/knockdown validation.
• Do not mix plate handling between groups. Cell loss during aspiration or washing can become a treatment-independent source of variation.

Frequently asked questions

Can In-Cell ELISA quantify absolute protein concentration?

Usually not without a carefully validated calibration model. The method is most defensible for relative comparison of fixed-cell target signal after background correction and cell-number normalisation.

Should I use total protein or a housekeeping protein for normalisation?

A direct cell-number or total-cell stain is often more robust because treatment can alter traditional housekeeping proteins. If a housekeeping protein is used, validate that it remains stable across the full experimental range.

Can In-Cell ELISA measure phosphorylation?

Yes, provided the phospho-specific antibody is validated for fixed-cell use and the signal is interpreted alongside total target abundance or a robust cell-normalisation readout.

Can this replace western blotting?

It can provide a higher-throughput quantitative readout once specificity is established, but it does not provide molecular-weight information. Western blotting remains useful for confirming antibody specificity and isoform size.

Related ABMIUM protocols

• Immunocytochemistry (ICC) Protocol
• Indirect ELISA Protocol
• Western Blot Protocol

References and journal sources

1. Boveia V, Schutz-Geschwender A. Quantitative Analysis of Signal Transduction with In-Cell Western Immunofluorescence Assays. Methods Mol Biol. 2015;1314:115–130. doi:10.1007/978-1-4939-2718-0_13.
2. Moerke NJ, Hoffman GR. Development of in-cell Western assays using far-red fluorophores. Curr Protoc Chem Biol. 2011;3:39–52. doi:10.1002/9780470559277.ch100153.
3. Quantification of rapid myosin regulatory light chain phosphorylation using high-throughput in-cell Western assays: comparison to Western immunoblots. PLoS ONE. 2010;5:e9965. doi:10.1371/journal.pone.0009965.
4. Pal AS, Agredo AM, Kasinski AL. In-Cell Western Protocol for Semi-High-Throughput Screening of Single Clones. Bio Protoc. 2022;12:e4489. doi:10.21769/BioProtoc.4489.

Relevant ABMIUM products

Product suitability depends on the target, primary-antibody host species and detection chemistry. Review each product page and supporting documents before use.

• Goat Anti-Mouse IgG(H+L), HRP conjugated — ELISA-compatible secondary detection for compatible mouse primary antibodies.
• Goat Anti-Rabbit IgG(H+L), HRP conjugated — ELISA-compatible secondary detection for compatible rabbit primary antibodies.
• Goat Anti-Rabbit IgG(H+L), FITC conjugated — IF/ICC-compatible fluorescent secondary for compatible rabbit primary antibodies.
• Goat Anti-Mouse IgG(H+L), FITC conjugated — IF/ICC-compatible fluorescent secondary for compatible mouse primary antibodies.

Explore more with ABMIUM

For a target-specific assay, use Find your MATCH and tell us the target, species, cell type and intended readout. You can also explore IF/ICC-compatible antibodies, search phospho-specific antibodies, or continue to the ICC Protocol and Western Blot Protocol.